Cargando…

Magnetic Resonance Imaging (MRI) of Intratumoral Voxel Heterogeneity as a Potential Response Biomarker: Assessment in a HER2+ Esophageal Adenocarcinoma Xenograft Following Trastuzumab and/or Cisplatin Therapy()()

We evaluated magnetic resonance imaging (MRI) voxel heterogeneity following trastuzumab and/or cisplatin in a HER2+ esophageal xenograft (OE19) as a potential response biomarker. OE19 xenografts treated with saline (controls), monotherapy, or combined cisplatin and trastuzumab underwent 9.4-T MRI. T...

Descripción completa

Detalles Bibliográficos
Autores principales:	Yip, Connie, Weeks, Amanda, Shaw, Karen, Siddique, Musib, Chang, Fuju, Landau, David B., Cook, Gary JR., Goh, Vicky
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Neoplasia Press 2017
Materias:	Original article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5408154/ https://www.ncbi.nlm.nih.gov/pubmed/28456115 http://dx.doi.org/10.1016/j.tranon.2017.03.006

Ejemplares similares

Imaging body composition in cancer patients: visceral obesity, sarcopenia and sarcopenic obesity may impact on clinical outcome
por: Yip, Connie, et al.
Publicado: (2015)

Challenges and Promises of PET Radiomics
por: Cook, Gary J.R., et al.
Publicado: (2018)

Radiomics in esophageal and gastric cancer
por: Sah, Bert-Ram, et al.
Publicado: (2019)

Clinical impact of intratumoral HER2 heterogeneity on trastuzumab efficacy in patients with HER2-positive gastric cancer
por: Wakatsuki, Takeru, et al.
Publicado: (2018)

The effects of segmentation algorithms on the measurement of (18)F-FDG PET texture parameters in non-small cell lung cancer
por: Bashir, Usman, et al.
Publicado: (2017)

Neratinib plus trastuzumab is superior to pertuzumab plus trastuzumab in HER2-positive breast cancer xenograft models
por: Veeraraghavan, Jamunarani, et al.
Publicado: (2021)

Characterizing Trastuzumab-Induced Alterations in Intratumoral Heterogeneity with Quantitative Imaging and Immunohistochemistry in HER2+ Breast Cancer
por: Syed, Anum K., et al.
Publicado: (2018)

Heterogeneous distribution of trastuzumab in HER2-positive xenografts and metastases: role of the tumor microenvironment
por: Baker, Jennifer Hazel Elizabeth, et al.
Publicado: (2018)

Targeting HER3 or MEK overcomes acquired Trastuzumab resistance in HER2-positive gastric cancer-derived xenograft
por: Zhang, Mengqi, et al.
Publicado: (2022)

Does Measurement of First-Order and Heterogeneity Parameters Improve Response Assessment of Bone Metastases in Breast Cancer Compared to SUV(max) in [(18)F]fluoride and [(18)F]FDG PET?
por: Azad, Gurdip K., et al.
Publicado: (2018)

The effect of post-injection (18)F-FDG PET scanning time on texture analysis of peripheral nerve sheath tumours in neurofibromatosis-1
por: Lovat, Eitan, et al.
Publicado: (2017)

Predicting Response to Neoadjuvant Chemotherapy with PET Imaging Using Convolutional Neural Networks
por: Ypsilantis, Petros-Pavlos, et al.
Publicado: (2015)

Clinical significance of intratumoral HER2 heterogeneity on trastuzumab efficacy using endoscopic biopsy specimens in patients with advanced HER2 positive gastric cancer
por: Yagi, Shusuke, et al.
Publicado: (2018)

A Retrospective Comparison of Trastuzumab Plus Cisplatin and Trastuzumab Plus Capecitabine in Elderly HER2-Positive Advanced Gastric Cancer Patients
por: Zhu, Bo, et al.
Publicado: (2015)

Multiparametric MR and PET Imaging of Intratumoral Biological Heterogeneity in Patients with Metastatic Lung Cancer Using Voxel-by-Voxel Analysis
por: Metz, Stephan, et al.
Publicado: (2015)

T-bet expression in intratumoral lymphoid structures after neoadjuvant trastuzumab plus docetaxel for HER2-overexpressing breast carcinoma predicts survival
por: Ladoire, S, et al.
Publicado: (2011)

Augmented inhibition of angiogenesis by combination of HER2 antibody chA21 and trastuzumab in human ovarian carcinoma xenograft
por: Zhang, Anli, et al.
Publicado: (2010)

Is Response Assessment of Breast Cancer Bone Metastases Better with Measurement of (18)F-Fluoride Metabolic Flux Than with Measurement of (18)F-Fluoride PET/CT SUV?
por: Azad, Gurdip K., et al.
Publicado: (2019)

Efficacy of Trastuzumab + Cisplatin Combined with Irinotecan on the Quality of Life of Patients with Advanced Her-2 Positive Gastric Cancer
por: Yang, Yu-Xin, et al.
Publicado: (2022)

Evaluation of Trastuzumab Anti-Tumor Efficacy and its Correlation with HER-2 Status in Patient-Derived Gastric Adenocarcinoma Xenograft Models
por: Chen, Hao, et al.
Publicado: (2015)

Mode of action of pertuzumab in combination with trastuzumab plus docetaxel therapy in a HER2-positive breast cancer xenograft model
por: Yamashita-Kashima, Yoriko, et al.
Publicado: (2017)

Development of the CK‐MB‐1 trastuzumab‐resistant HER2‐positive breast cancer cell line and xenograft animal models
por: Chung, Wei‐Pang, et al.
Publicado: (2021)

Measurement of (18)F-FDG PET tumor heterogeneity improves early assessment of response to bevacizumab compared with the standard size and uptake metrics in a colorectal cancer model
por: Bashir, Usman, et al.
Publicado: (2019)

Phase II study of trastuzumab in combination with S-1 plus cisplatin in HER2-positive gastric cancer (HERBIS-1)
por: Kurokawa, Y, et al.
Publicado: (2014)

Radionuclide Therapy of HER2-Expressing Xenografts Using [(177)Lu]Lu-ABY-027 Affibody Molecule Alone and in Combination with Trastuzumab
por: Liu, Yongsheng, et al.
Publicado: (2023)

Effect of Trastuzumab–HER2 Complex Formation on Stress-Induced Modifications in the CDRs of Trastuzumab
por: Spanov, Baubek, et al.
Publicado: (2022)

Intratumoral Injection of an Adriamycin Immunoconjugate against Human Pancreatic Cancer Xenografts
por: Kondo, Yasuyuki, et al.
Publicado: (1995)

Intratumor Heterogeneity in Interstitial Fluid Pressure in Cervical and Pancreatic Carcinoma Xenografts()()
por: Hansem, Lise Mari K., et al.
Publicado: (2019)

HER2+ esophageal carcinoma leptomeningeal metastases treated with intrathecal trastuzumab regimen
por: Wu, Scott A, et al.
Publicado: (2023)

Evaluating treatment response using DW-MRI and DCE-MRI in trastuzumab responsive and resistant HER2-overexpressing human breast cancer xenografts
por: Whisenant, Jennifer G., et al.
Publicado: (2014)

HER2 therapy: Molecular mechanisms of trastuzumab resistance
por: Nahta, Rita, et al.
Publicado: (2006)

Targeting HER2 in breast cancer: beyond trastuzumab
por: Winer, EP
Publicado: (2011)

Quantification of Trastuzumab–HER2 Engagement In Vitro and In Vivo
por: Rudkouskaya, Alena, et al.
Publicado: (2020)

Enhanced Anti‐tumor Effect of Trastuzumab in Combination with Cisplatin
por: Naruse, Ichiro, et al.
Publicado: (2002)

Trastuzumab‐based near‐infrared photoimmunotherapy in xenograft mouse of breast cancer
por: Yamashita, Susumu, et al.
Publicado: (2022)

Trastuzumab increases the sensitivity of HER2-amplified human gastric cancer cells to oxaliplatin and cisplatin by affecting the expression of telomere-associated proteins
por: LIU, YONGPING, et al.
Publicado: (2015)

HER2 Intratumoral Heterogeneity in Breast Cancer, an Evolving Concept
por: Hou, Yanjun, et al.
Publicado: (2023)

Primary Rectal Cancer: Repeatability of Global and Local-Regional MR Imaging Texture Features
por: Gourtsoyianni, Sofia, et al.
Publicado: (2017)

Fractionated Therapy of HER2-Expressing Breast and Ovarian Cancer Xenografts in Mice with Targeted Alpha Emitting (227)Th-DOTA-p-benzyl-trastuzumab
por: Heyerdahl, Helen, et al.
Publicado: (2012)

Multimodal Imaging Technology Effectively Monitors HER2 Expression in Tumors Using Trastuzumab-Coupled Organic Nanoparticles in Patient-Derived Xenograft Mice Models
por: Wen, Li, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_kli02598ng6mu3su37qipb4m64